Pick Topic
Review Topic
List Experts
Examine Expert
Save Expert
  Site Guide ··   
Melanoma: HELP
Articles by Abigail S. Caudle
Based on 2 articles published since 2008

Between 2008 and 2019, Abigail Caudle wrote the following 2 articles about Melanoma.
+ Citations + Abstracts
1 Review Metastasectomy for stage IV melanoma: for whom and how much? 2011

Caudle, Abigail S / Ross, Merrick I. ·Department of Surgical Oncology, University of Texas MD Anderson Cancer Center, 1515 Holcombe Boulevard, Unit 444, Houston, TX 77030, USA. ascaudle@mdanderson.org ·Surg Oncol Clin N Am · Pubmed #21111963.

ABSTRACT: Although the conventional paradigm for treating metastatic melanoma relies on systemic therapies, a surgical approach should be strongly considered in selected patients. A surgical approach may not be appropriate for all patients, but it can offer a rapid clearance of disease without the toxicity of systemic therapy. Patient selection is of paramount importance for surgery to be effective. The rationale for surgical intervention in the management of metastatic melanoma, selection factors to be considered, published results, and future directions are discussed in this article.

2 Article A multi-institutional experience of isolated limb infusion: defining response and toxicity in the US. 2009

Beasley, Georgia M / Caudle, Abigail / Petersen, Rebecca P / McMahon, Nicole S / Padussis, James / Mosca, Paul J / Zager, Jonathan S / Hochwald, Steven N / Grobmyer, Stephen R / Delman, Keith A / Andtbacka, Robert H / Noyes, R Dirk / Kane, John M / Seigler, Hilliard / Pruitt, Scott K / Ross, Merrick I / Tyler, Douglas S. ·Department of Surgery, Duke University Medical Center, Durham, NC 27710, USA. ·J Am Coll Surg · Pubmed #19476821.

ABSTRACT: BACKGROUND: Isolated limb infusion (ILI) is a minimally invasive approach for treating in-transit extremity melanoma, with only two US single-center studies reported. Establishing response and toxicity to ILI as compared with hyperthermic isolated limb perfusion is important for optimizing future regional chemotherapeutic strategies in melanoma. STUDY DESIGN: Patient characteristics and procedural variables were collected retrospectively from 162 ILIs performed at 8 institutions (2001 to 2008) and compared using chi-square and Student's t-test. ILIs were performed for 30 minutes in patients with in-transit melanoma. Melphalan dose was corrected for ideal body weight (IBW) in 42% (n = 68) of procedures. Response was determined at 3 months by Response Evaluation Criteria in Solid Tumors; toxicity was assessed using the Wieberdink Limb Toxicity Scale. RESULTS: In 128 evaluable patients, complete response rate was 31%, partial response rate was 33%, and there was no response in 36% of patients. For all patients (n = 162), 36% had Wieberdink toxicity grade >or=3 with one toxicity-related amputation. On multivariate analysis, smaller limb volumes were associated with better overall response (p = 0.021). Use of papaverine in the circuit to achieve cutaneous vasodilation was associated with better response (p < 0.001) but higher risk of grade >or=3 toxicity (p = 0.001). Correction of melphalan dose for ideal body weight did not alter complete response (p = 0.345), but did lead to marked reduction in toxicity (p < 0.001). CONCLUSIONS: In the first multi-institutional analysis of ILI, a complete response rate of 31% was achieved with acceptable toxicity demonstrating this procedure to be a reasonable alternative to hyperthermic isolated limb perfusion in the management of advanced extremity melanoma.